Trials / Unknown
UnknownNCT05622123
BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation
The Effects of Faecal Microbiota Transplantation on Beta Cell Preservation in Patients With Newly Diagnosed Type 1 Diabetes
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main goal is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes
Detailed description
The incidence of Type 1 Diabetes Mellitus (T1D) has tripled in the last thirty years, and T1D is associated with a lifelong increase of considerable morbidity and mortality compared to healthy subjects. As the increased T1D incidence is primarily observed in subjects who are not genetically predisposed, environmental factors including altered diet, antibiotic use as well as mode of birth have been suggested to play a role, and these factors have invariably been linked to changes in the gut microbiome. Indeed, an altered composition of the faecal microbiota composition was observed in adolescent T1D patients. A previous study by de Groot et al. (2021) showed that faecal microbiota transplantation stops the decline in endogenous insulin production in newly diagnosed type 1 diabetes patients. However, it is unknown whether this is due to an increase in beta cell mass, or increased function of the remaining beta cells. In this study, the investigators aim to investigate whether beta cell mass (quantified by 68Ga-NODAGA-exendin-4 PET/CT imaging) is correlated to beta cell function after autologous faecal microbial transplantation in patients with newly diagnosed type 1 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-NODAGA-Exendin-4 | PET/CT imaging after injection with 68Ga-NODAGA-exendin-4 |
Timeline
- Start date
- 2023-02-23
- Primary completion
- 2024-02-28
- Completion
- 2024-03-30
- First posted
- 2022-11-18
- Last updated
- 2023-04-04
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05622123. Inclusion in this directory is not an endorsement.